drugset
drugset / Trial / NCT01984398

Comparison of Two Formulations of Androxal

NCT01984398 ↗

Phase 1 Completed 16 enrolled Repros Therapeutics Inc.
RandomizedCrossoverQuadruple-blindTreatment

Summary

To determine and compare the pharmacokinetics (PK) of a single dose of each of two formulations Androxal

Timeline

Start
2013-12-31
Primary completion
2013-12-31
Completion
2013-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Androxal Unknown 12.5 mg —
Subject Androxal Unknown 25 mg —

Indications

No indication recorded.